Australia's Clarity Pharmaceutical gains on reporting first prostate cancer treatment
15/04/2025 04:22
** Shares of Clarity Pharmaceuticals CU6.AX rise 6% to A$1.850, ** Stock hits its highest level since April 3 ** Radiopharmaceutical co announces the treatment of the first participant with the first dose of Cu-SAR-bisPSMA, a radioactive substance used to target prostate cancer cells ** CU6 down 55.7% YTD, including current session's moves (Reporting by Manasi Dasa in Bengaluru) ((Manasi.DasaSundeep@thomsonreuters.com))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial